GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial)

Research summary

Type 1 diabetes (T1D) is an immune-mediated disease in which insulin-producing betacells are completely or near completely destroyed, resulting in life-long dependence on exogenous insulin. It is a chronic and potentially disabling disease that represents a major public health and clinical concern. The number of patients diagnosed with T1D each year is increasing and is approaching an epidemic level in some countries that track this information The POInT study examines whether the development of T1D can be prevented in children with an increased risk of T1D through preventive treatment with insulin. Infants who have a high risk of developing type 1 diabetes will be identified in the INGR1D screening study and will then be invited to take part in the POInT study. In POInT, insulin will be given to children aged between 4-7 months every day until their 3rd birthday to see if it reduces the incidence of diabetes in childhood. The insulin will be given orally (via mouth) as a powder and is not used to lower blood glucose levels. Instead, it serves to train and regulate the immune system.

Principal Investigator

Dr Rachel Besser

Contact us

Email: raquel.lomas@ndm.ox.ac.uk

IRAS number

237301